Flurry for Forest finale

In a flurry of filings, activist investor Carl Icahn and his latest life sciences target Forest Laboratories Inc. (NYSE:FRX) postured for investors ahead of the company's annual meeting on Thursday this week. At least three proxy advisory services weighed in, mostly in support of company board nominees.

The adversaries, who have been trading barbed filings for several months, each fine-tuned their arguments concerning Forest's stock performance and fundamentals, and the qualifications of the competing board nominees...